PubMed · 2015 · 16 citations · 75 references
MedicineOncologyPharmacotherapyCancer GeneticsGenitourinary OncologyMolecular OncologyKidney CancerMtor Inhibitor TherapyRenal Cell CarcinomaRenal NeoplasmsTargeted Cancer TherapyTyrosine Kinase InhibitorsMtor InhibitionRenal MalignancyTargeted Molecular TherapyVascular Endothelial Growth Factor Inhibition
Non-clear cell renal cell carcinomas (RCCs) represent a heterogeneous group of diseases with distinct molecular drivers, histologies, and clinical outcomes. Their low incidence and heterogeneity have resulted in a lack of studies that address the optimal strategies for each subtype. This article (the second in a 2-part series) reviews the current targeted therapies approved for RCC, such as the vascular endothelial growth factor receptor tyrosine kinase inhibitors and the mammalian target of rapamycin inhibitors. Ongoing studies will provide more information regarding the role of these agents in non-clear cell RCC. Ultimately, enhanced understanding of genetic triggers and the development of more tailored treatments remain imperative to improve outcomes in non-clear cell RCC.
75
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations
Medicine, Oncology, Chemotherapy +10